Publications
Publications
Show Results For
- All HBS Web
(627)
- Faculty Publications (117)
Diseases
→
Page 1 of 117
Results →
- November 2024
- Supplement
AlphaGo (C): Birth of a New Intelligence
By: Shikhar Ghosh and Shweta Bagai
This case, the final of a three-part series, explores DeepMind's pivotal transition from mastering games to solving real-world scientific challenges. In December 2020, DeepMind's AI system AlphaFold 2 achieved a breakthrough by solving protein folding—a 50-year-old... View Details
Keywords: Autonomy; Deep Learning; Drug Discovery; Healthcare Innovation; Neural Networks; Scientific Research; Technology Startup; AI and Machine Learning; Technological Innovation; Research and Development; Business Model; Business Strategy; Open Source Distribution; Technology Industry; United States
- July 2024
- Case
Gates Ventures: Making Alzheimer's a Forgotten Past
By: Satish Tadikonda, William Marks, Shardule Shah and Calvin Marambo
After a personal journey and interest in Alzheimer's Disease (AD) by Bill Gates, Gates Ventures set out to find the best way to accelerate innovation in the field of AD. In partnership with the Alzheimer's Drug Discovery Foundation, Gates Ventures created the... View Details
- April 2024 (Revised December 2024)
- Case
Anthropic: Building Safe AI
By: Shikhar Ghosh and Shweta Bagai
In late 2024, Anthropic, a leading AI safety and research company, achieved a significant breakthrough with computer use capabilities that allowed AI to interact with computers like humans. Co-founded by former OpenAI employees and known for its generative AI... View Details
- March 2024 (Revised September 2024)
- Case
Norway: An Embarrassment of Riches
By: Sophus A. Reinert, Forest Reinhardt and Jens-Henrik Munthe-Kaas
- February 2024 (Revised December 2024)
- Case
Best Buy Health: Enabling Care at Home
This case explores retailer Best Buy’s decision to enter health care. Best Buy Health aims to enable care at home across three prongs: consumer health, active aging, and virtual care. A key pillar of Best Buy Health's strategy is leveraging the Geek Squad—the company's... View Details
- January 2024
- Article
Cost of Exempting Sole Orphan Drugs from Medicare Negotiation
By: Matthew Vogel, Olivia Zhao, William B. Feldman, Amitabh Chandra, Aaron S. Kesselheim and Benjamin N. Rome
Importance: The Inflation Reduction Act (IRA) requires Medicare to negotiate prices for some high-spending drugs but exempts drugs approved solely for the treatment of a single rare disease.
Objective: To estimate Medicare spending and global... View Details
Objective: To estimate Medicare spending and global... View Details
- 2023
- Article
Benchmarking Large Language Models on CMExam—A Comprehensive Chinese Medical Exam Dataset
By: Junling Liu, Peilin Zhou, Yining Hua, Dading Chong, Zhongyu Tian, Andrew Liu, Helin Wang, Chenyu You, Zhenhua Guo, Lei Zhu and Michael Lingzhi Li
Recent advancements in large language models (LLMs) have transformed the field of question answering (QA). However, evaluating LLMs in the medical field is challenging due to the lack of standardized and comprehensive datasets. To address this gap, we introduce CMExam,... View Details
- November 2023 (Revised April 2024)
- Case
BiomX: Bringing Phage Back to the Stage
By: Paul A. Gompers, Elie Ofek, Orna Dan and Emilie Billaud
In the spring of 2023, and following the favorable results of a trial involving its phage cocktail for treating lung infections among cystic fibrosis (CF) patients, the leadership of BiomX had several critical issues to wrestle with. First, given its precarious... View Details
- October 2023
- Case
Vida Health: Transforming Chronic Disease Treatment
By: William Sahlman and Nicole Tempest Keller
San Francisco based Vida Health, founded by Stephanie Tilenius, former vice president of Commerce and Payments at Google, was a B2B digital health startup focused on the treatment of cardiometabolic conditions, such as diabetes and obesity. Its innovative digital... View Details
- September 2023
- Case
Healthy.io: The Negotiation for the Medical Selfie
By: Amit Goldenberg and Kumba Sennaar
Healthy.io, an Israeli digital health company, prepares to enter the U.S. market with its chronic kidney disease test. A product safety approval is delayed, putting the company’s cash runway at risk. How should the CEO negotiate his offer to insurance companies ahead... View Details
- August 2023
- Article
Explaining Machine Learning Models with Interactive Natural Language Conversations Using TalkToModel
By: Dylan Slack, Satyapriya Krishna, Himabindu Lakkaraju and Sameer Singh
Practitioners increasingly use machine learning (ML) models, yet models have become more complex and harder to understand. To understand complex models, researchers have proposed techniques to explain model predictions. However, practitioners struggle to use... View Details
- June 2023 (Revised July 2024)
- Case
Biogen and the Aduhelm Melee
By: Amitabh Chandra and Lauren Gunasti
Alzheimer's Disease is a devastating condition affecting millions of Americans. At this time, there is no cure. In 2021, Biogen's Aduhelm (aducanumab) received FDA approval under the accelerated approval pathway after a controversial approval process.
This... View Details
This... View Details
- June 2023
- Case
Verve Therapeutics: Taking DNA Editing to Heart
By: Shikhar Ghosh and Shweta Bagai
Verve Therapeutics, a public biotech company based in Boston, created a novel approach to addressing cardiovascular disease (CVD) - a leading cause of deaths globally. The company's approach was a single shot treatment to permanently lower cholesterol, thus reducing... View Details
- May 2023 (Revised June 2023)
- Case
Novartis (A): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
- May 2023 (Revised June 2023)
- Supplement
Novartis (B): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
- May 2023 (Revised June 2023)
- Supplement
Novartis (C): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
- March 2023 (Revised March 2025)
- Case
Close Concerns: Diabetes Research and Advocacy
By: Regina Herzlinger and Brian L. Walker
Diagnosed with diabetes at the age of 18, Kelly Close understood the importance of balancing consistency and iteration. This principle had also informed her professional work, which started with a rapid promotion from financial analyst at Goldman Sachs to an analyst... View Details
- January 2023
- Supplement
Apple: Privacy vs. Safety (B)
By: Henry McGee, Nien-hê Hsieh and Christian Godwin
In 2020, as the COVID-19 pandemic swept across the globe, Apple and Google partnered to develop a contact tracing application that would collect information about users infected with the disease and notify those who they had been in contact with. While Apple/Google’s... View Details
Keywords: Iphone; Encryption; Data Privacy; Customers; Customer Focus and Relationships; Decision Making; Ethics; Values and Beliefs; Globalized Firms and Management; Government and Politics; Health; Health Pandemics; Leadership; Markets; Safety; Social Issues; Information Technology; Telecommunications Industry; Technology Industry; Consumer Products Industry; Electronics Industry; Health Industry; United States; Europe
- January 2023 (Revised September 2024)
- Supplement
The END Fund (B)
By: V. Kasturi Rangan and Courtney Han
Founded in 2012, the END fund focused on eliminating five Neglected Tropical Diseases that accounted for 80% of the tropical diseases affecting nearly 1.5 billion people worldwide. Its roughly $25 million/year annual budget was fully committed when it got news that the... View Details
- January 2023
- Case
The END Fund: To Eliminate Neglected Tropical Diseases
By: V. Kasturi Rangan and Courtney Han
Founded in 2012, the END fund focused on eliminating five Neglected Tropical Diseases that accounted for 80% of the tropical diseases affecting nearly 1.5 billion people worldwide. Its roughly $25 million/year annual budget was fully committed when it got news that the... View Details